GLP-2 analogue
Teduglutide
Brand names: Revestive
Adult dose
Dose: 0.05 mg/kg SC OD
Route: SC
Frequency: OD
Clinical pearls
- Short bowel syndrome with parenteral nutrition dependence
- Specialist GI; colonoscopy pre-treatment + every 5 years
Contraindications
- Active GI / hepatobiliary malignancy
- Severe hepatic impairment
- Hypersensitivity
Side effects
- Abdominal pain
- Nausea
- Stomal complications
- Pancreatic / biliary disease
- Polyp formation
- Fluid overload
Interactions
- May enhance absorption of other drugs
Monitoring
- FBC
- LFTs
- Lipase
- Colonoscopy
Reference: BNF; NICE HST12; SmPC; https://bnf.nice.org.uk/drugs/teduglutide/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021